Rapamycin-eluting stents for unprotected left main coronary artery stenosis in coronary atherosclerosis in the older adults: study protocol for a prospective, non-randomized, controlled trial and preliminary results

doi:10.3969/j.issn.2095-4344.0887

Abstract

Abstract:

BACKGROUND: Coronary artery bypass grafting (CABG) is the gold standard therapy for unprotected left main coronary artery (ULMCA) stenosis in coronary atherosclerosis. However, the treatment of ULMCA stenosis using drug-eluting stents has recently been reported to lead to a relatively low incidence of cardiovascular events.Thus,drug-eluting stents are a potential surrogate for CABG,and could become the new gold standard treatment for ULMCA stenosis; however, this issue remains controversial.

OBJECTIVE: To explore the safety and efficacy of CABG versus rapamycin-eluting stents for ULMCA stenosis in older adult patients with degenerative coronary atherosclerosis.

METHODS: The proposed prospective, non-randomized, controlled trial will include 224 older adult patients with degenerative coronary atherosclerosis with ULMCA stenosis being treated at the Department of Cardiology at Taihe Hospital and Renmin Hospital of Shiyan, China. Patients will be divided into two groups in accordance with each patient’s treatment choice and indications (n=112/group): the stent group will receive rapamycin-eluting stents, while the CABG group will undergo CABG.All patients will be followed up at 9, 12, 24, and 36 months postoperatively. The primary outcome measure will be the rate of repeat revascularizations in the target lesion at 36 months postoperatively.The secondary outcome measures will be the rates of repeat revascularizations in the target lesion at 9, 12, and 24 months postoperatively, the rate of restenosis, mortality, causes of death, and survival at 9, 12, 24, and 36 months postoperatively, and the angiographic appearance of the diseased vessels preoperatively and at 9, 12, 24, and 36 months postoperatively. The safety indicator will be the incidence of major adverse cardiac and cerebrovascular events at 9, 12, 24, and 36 months postoperatively. Eighty-six older adult patients with degenerative coronary atherosclerosis who underwent treatment of ULMCA stenosis between January 2016 and December 2017 were included in a pilot study. Pilot study results showed that the stent group (n=48) had a significantly reduced waiting time for surgery, hospitalization time, and rate of complete revascularizations in the target lesion compared with the CABG group (n=38) (P < 0.05). At 6 months postoperatively, there were no significant differences between the two groups in mortality, and incidences of myocardial infarction, repeat revascularizations in the target lesion, and cardiovascular events. The trial was approved by the Ethics Committee of Taihe Hospital (approval No. TH005X) in July 2017 and by the Ethics Committee of Renmin Hospital of Shiyan (approval No. RM011X) in July 2017. All the patients will provide written informed consent with the premise of fully understanding the treatment plan. The study protocol will follow the relevant laws and regulations of the Declaration of Helsinki and relevant hospital’s ethical principles. Design of the trial was completed in January 2018. Recruitment will be initiated in August 2018 and it is expected to be completed in August 2019. Data analysis will be conducted in October 2022 and the trial will be completed in December 2022. The results of the study will be disseminated through presentations at scientific meetings and/or in peer-reviewed publications. The trial has been registered with the Chinese Clinical Trial Registry (registration No. ChiCTR1800016413) and the version number is 1.0

DISCUSSION: The results of this study will indicate the medium- and long-term efficacy and safety of rapamycin-eluting stents versus CABG in older adult patients with ULMCA stenosis, and then identify which of these two treatments has better prognosis, thereby screening out the optimal strategy for treating ULMCA.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

Key words: Tissue Engineering, Stents, Coronary Stenosis

CLC Number:

R318

Chen Wei, Fang Zhi-cheng, Zheng Xiang, Liu Bo-yi, Zhao Ji-xian, Liao Ying-ying. Rapamycin-eluting stents for unprotected left main coronary artery stenosis in coronary atherosclerosis in the older adults: study protocol for a prospective, non-randomized, controlled trial and preliminary results[J]. Chinese Journal of Tissue Engineering Research, 2018, 22(18): 2890-2895.

Figures/Tables 3

References

[1] Wang L, Li HC, Zhou J, et al. Correlation between the GP78 Gene Polymorphism and Coronary Atherosclerotic Heart Disease. Hellenic J Cardiol. 2018;59(1):8-13.

[2] Shi JR, Tian CJ, Zeng Q, et al. Expressions of Mast Cell Tryptase and Brain Natriuretic Peptide in Myocardium of Sudden Death due to Hypersensitivity and Coronary Atherosclerotic Heart Disease. Fa Yi Xue Zazhi. 2016;32(3):161-164.

[3] Yang RH, Liu YF, Wang XJ, et al. Correlation between high density lipoprotein and monocyte subpopulations among stable coronary atherosclerotic heart disease patients. Int J ClinExp Med. 2015;8(9):16969-16977.

[4] Wong MC, Zhang DX, Wang HH. Rapid emergence of atherosclerosis in Asia: a systematic review of coronary atherosclerotic heart disease epidemiology and implications for prevention and control strategies. Curr Opin Lipidol. 2015;26(4): 257-269.

[5] 宋昌鹏,王德昭,胡宏宇,等.3.0T高分辨率磁共振评价冠状动脉粥样硬化患者的颈动脉斑块特征[J].中华心血管病杂志,2016,44(1): 38-42.

[6] Ellis SG, Tamai H, Nobuyoshi M, et al. Contemporary percutaneous treatment of unprotected left main coronary stenoses: initial results from a multicenter registry analysis 1994-1996. Circulation. 1997;96(11):3867-3872.

[7] Kelley MP, Klugherz BD, Hashemi SM, et al. One-year clinical outcomes of protected and unprotected left main coronary artery stenting. Eur Heart J. 2003;24(17):1554-1559.

[8] Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation. 1995;91(9):2335-2344.

[9] Park SJ, Kim YH, Lee BK, et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol. 2005;45(3):351-356.

[10] Tan Q, Wang Q, Liu D, et al. Intravascular ultrasound-guided unprotected left main coronary artery stenting in the elderly. Saudi Med J. 2015;36(5):549-553.

[11] Cassese S, Kufner S, Xhepa E, et al. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. Clin Res Cardiol. 2016;105(7):575-584.

[12] Ray S, Mazumder A, Kumar S, et al. Angioplasty of unprotected left main coronary stenosis: real world experience of a single-operator group from eastern India. Indian Heart J. 2016;68(1):28-35.

[13] 周玉杰,贾德安.批阅三载增删十次-《冠状动脉粥样硬化性心脏病诊断标准》诞生记[J].中国卫生标准管理,2010,1(4):20-21.

[14] 杨菲菲,王禹,荆晶,等.无保护左主干病变支架介入治疗后冠状动脉造影随访结果分析[J].中华老年心脑血管病杂志,2010,12(9): 795-798.

[15] 高好考,王琼,李寰,等.药物涂层球囊在冠状动脉前降支支架内再狭窄复杂病变的安全性观察[J].岭南心血管病杂志,2017,23(6):649-652.

[16] 蔡俊锋,邬祎程,孙延军,等.不同手术方式重建左前降支血运的效果[J].中华胸心血管外科杂志,2013,29(4):209-211.

[17] Brener SJ, Galla JM, Bryant R 3rd, et al. Comparison of percutaneous versus surgical revascularization of severe unprotected left main coronary stenosis in matched patients. Am J Cardiol. 2008;101(2):169-172.